Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Dr Karen Lazenby appointed as Registrar: Systems and Administration
2015-11-11


Dr Karen Lazenby, Registrar: Systems and Administration

Dr Karen Lazenby, former Director: Client Service Centre at the University of Pretoria (UP), was appointed as Registrar: Systems and Administration at the University of the Free State (UFS) as from 1 November 2015. She will be responsible for student enrolment, administration and services, and International Affairs.

“We are extremely fortunate to have a person of the calibre and experience of Dr Lazenby to join the senior team to help us create a 21st century student-centred management system using the best technologies available. She is without question the leader in her field, and the UFS is delighted to have her as part of the Kovsie community,” says Prof Jonathan Jansen, Vice-Chancellor and Rector of the UFS.

Educational background

Dr Lazenby completed the BA (1992) and Honours (1993) degrees in English (cum laude) at the University of Potchefstroom before pursuing a Diploma in Tertiary Education (1996) and a Master's Degree in Computer Integrated Education (1998) at the University of Pretoria. She obtained a PhD in Education in 2003 on the topic ‘Technology and educational innovation: A case study of the virtual campus of the University of Pretoria’ and an Executive MBA from the University of Cape Town in 2006.

A track record to reckon with


Dr Lazenby started her career in higher education as a lecturer in Communication at the VaalTriangle Technikon in 1994, and was appointed as Head of Academic Staff Development the following year.  A year later, she joined Technikon SA as instructional designer at the Centre for Courseware Design and Development, and in 1997 she was appointed as Manager of Institutional Research. She was subsequently seconded to establish TSA Online and coordinate institutional technology. Dr Lazenby was appointed as a project manager at the department of Education Innovation at the University of Pretoria in 1998 where she implemented WebCT/Blackboard, online applications and payments, and student and lecturer portals (virtual campus). In 2000 she was appointed as Deputy Director: Electronic Education.

She was seconded by the UP Executive to establish the Client Service Centre in 2001 to provide integrated, efficient and effective services to students and other clients of the University. During her time as Director: Client Service Centre, she was inter alia, responsible for information and data governance, the intranet, website and call centre of the university, student recruitment, publications, application for study support, study finance, postgraduate scholarships, student accounts, payments, residence placement, access cards and parking, the graduate career office, and international student division. In 2005, she also acted as Director: Corporate Communication and Marketing.

Her vision for the UFS

“I would like to get the university's student administration to such a point that academic staff can focus on teaching and research. Streamlining the enrolment process so that we may see the necessary yield required in terms of our growth target as a university, is my other goal.” She added that capitalising on the strong international positioning of the UFS achieved by Prof Jansen, is a mission she intends to carry out. "I am grateful for the opportunity to work with Prof Jansen and the senior management team and am delighted to be part of the Kovsie community."

Dr Lazenby has published several articles and presented nineteen papers at international conferences.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept